Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA User Fees

Set Alert for FDA User Fees

US FDA User Fee Conundrum: Collections Increase After 25% PDUFA Rate Hike

With likely more fee-paying applications arriving at the agency, sponsors may be wondering whether user fees should have been increased as much as they were at the start of FY 2024.

User Fees Drug Review

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.

FDA Legislation

Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?

EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.

Generic Drugs Regional Comparisons

CDER, CBER Post FY 2023 Employee Gains, But Behind User Fee Hiring Goals

US FDA’s drug center reported a net increase of more than 300 employees in FY 2023, while the biologics center saw an overall increase of more than 30.

FDA User Fees

Congress Gives US FDA Austere Budget But Seeks Boosts On Inspections, IT, And ALS Activities

The minor cut would be masked by user fee revenue increases, but still would be the first time in at least a decade that agency's budget authority has dropped.

FDA Legislation

EMA's New Cost-Based Fee Structure Gets Final Go-Ahead From EU Ministers

EFPIA has welcomed the adoption of the new regulation, which will take effect from January 2025. However, it cautioned that the EMA and the national agencies needed to have the necessary resources to do their job and that the new fee structure should be supported by revisions to the EU pharmaceutical legislation.

Europe User Fees

Pink Sheet Podcast: US FDA Adcomm Schedule, CMS And Drug Importation, Missed User Fee Goals

Pink Sheet reporters and editors discuss the nearly wide open 2024 FDA advisory committee calendar, CMS’s impact on Florida’s drug importation plan, and the FDA’s many missed user fee goals in 2023.

Advisory Committees Pricing Debate

Pink Sheet Podcast: Looking Back And Looking Ahead: Key US and EU Legislation

Pink Sheet reporter and editors discuss key US and EU legislation that impacted 2023 and how it also could affect 2024, including EU legislative reform, US Medicare drug price negotiation, and the US Food and Drug Administration user fee reauthorization.

Pink Sheet Perspectives Legislation

ANDA Sponsors Need US FDA Permission To Avoid Last-Minute Label Update Delays

Under changes in the 2022 appropriations bill, generic drug applications can be approved even if a last-minute labeling update is needed, but sponsors risk product misbranding if the CBE is late.

Generic Drugs Review Pathway

US FDA’s No Recording Meetings Rule Already Appears Flexible

At least one sponsor has been recording meetings for several years, suggesting others could receive permission, but the decision comes with risks as well as benefits. As the agency again expands options for in-person meetings, sponsors may want to reflect on what works best for them.

Drug Review User Fees

Minutes Matter: Why The US FDA Refuses To Record Formal Meetings

Given confusion sometimes emerges about the content of formal meeting minutes, recording the meetings would seem like an easy solution, but also could muddy the administrative record.

Drug Review Regulation

Generics Review Data From US FDA Reveals Positives, Negatives For Industry

While a decline in complete response letters in FY 2023 is good, the continued drop in ANDA submissions could be a bad sign for the industry’s long-term health, a former FDA official worries.

Generic Drugs Review Pathway

US FDA Lab Test Rule Cites Explosion In Companion Diagnostics, COVID Lessons

FDA launches what it hopes will the final push to reform the regulatory oversight system for lab-developed tests by proposing a relatively rapid transition period to require essentially all LDTs to comply with the existing regulations for in vitro diagnostics. Legislation, litigation, and industry negotiation will likely shape the final product.

Personalized Medicine Diagnostics

US FDA’s Standard Application Assessment Makes A Comeback

After years where many more applications received priority assessments than standard assessments, in FY 2022 the difference narrowed.

User Fees Review Pathway

Preparing For A Shutdown: US FDA To Retain 81% Of Workforce, Thanks Mostly To User Fees

However, user fee carryover balances will not last forever and service cuts are inevitable if a shutdown lingers for several weeks.

FDA Legislation

EU Bodies Agree On Ways To Future-Proof EMA Funding System

EU ministers say that implementing an appropriate fee structure that is more in line with actual costs will promote innovation in the pharmaceutical sector while ensuring “fair access” to safe and effective medicines for patients.

Europe User Fees
See All